These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38793122)

  • 21. Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials.
    Cassese S; Byrne RA; Ndrepepa G; Kufner S; Wiebe J; Repp J; Schunkert H; Fusaro M; Kimura T; Kastrati A
    Lancet; 2016 Feb; 387(10018):537-544. PubMed ID: 26597771
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Magmaris: a new generation metallic sirolimus-eluting fully bioresorbable scaffold: present status and future perspectives.
    Rapetto C; Leoncini M
    J Thorac Dis; 2017 Aug; 9(Suppl 9):S903-S913. PubMed ID: 28894596
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction-TROFI II trial.
    Sabaté M; Windecker S; Iñiguez A; Okkels-Jensen L; Cequier A; Brugaletta S; Hofma SH; Räber L; Christiansen EH; Suttorp M; Pilgrim T; Anne van Es G; Sotomi Y; García-García HM; Onuma Y; Serruys PW
    Eur Heart J; 2016 Jan; 37(3):229-40. PubMed ID: 26405232
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of Acute Thrombogenicity for Metallic and Polymeric Bioabsorbable Scaffolds: Magmaris Versus Absorb in a Porcine Arteriovenous Shunt Model.
    Waksman R; Lipinski MJ; Acampado E; Cheng Q; Adams L; Torii S; Gai J; Torguson R; Hellinga DM; Westman PC; Joner M; Zumstein P; Kolodgie FD; Virmani R
    Circ Cardiovasc Interv; 2017 Aug; 10(8):. PubMed ID: 28801538
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of a Bioresorbable, Magnesium-Based Sirolimus-Eluting Stent with a Permanent, Everolimus-Eluting Metallic Stent for Treating Patients with Acute Coronary Syndrome: the PRAGUE-22 Study.
    Toušek P; Lazarák T; Varvařovský I; Nováčková M; Neuberg M; Kočka V
    Cardiovasc Drugs Ther; 2022 Dec; 36(6):1129-1136. PubMed ID: 34505954
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanical properties of the drug-eluting bioresorbable magnesium scaffold compared with polymeric scaffolds and a permanent metallic drug-eluting stent.
    Barkholt TØ; Webber B; Holm NR; Ormiston JA
    Catheter Cardiovasc Interv; 2020 Dec; 96(7):E674-E682. PubMed ID: 31710149
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Two-year clinical outcomes after implantation of an everolimus-eluting bioresorbable scaffold (Absorb) in stable angina and acute coronary syndrome patients. Single-centre real-life registry data.
    Briede I; Narbute I; Kumsars I; Sondore D; Trushinskis K; Jegere S; Latkovskis G; Strenge K; Rudzitis A; Erglis A
    Postepy Kardiol Interwencyjnej; 2018; 14(2):144-148. PubMed ID: 30008766
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents: A Propensity-Matched Comparison of the GHOST-EU and XIENCE V USA Registries.
    Tamburino C; Capranzano P; Gori T; Latib A; Lesiak M; Nef H; Caramanno G; Naber C; Mehilli J; Di Mario C; Sabaté M; Münzel T; Colombo A; Araszkiewicz A; Wiebe J; Geraci S; Jensen C; Mattesini A; Brugaletta S; Capodanno D
    JACC Cardiovasc Interv; 2016 Mar; 9(5):440-9. PubMed ID: 26875648
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The bioresorbable magnesium scaffold (Magmaris)-State of the art: From basic concept to clinical application.
    Rola P; Włodarczak S; Doroszko A; Lesiak M; Włodarczak A
    Catheter Cardiovasc Interv; 2022 Nov; 100(6):1051-1058. PubMed ID: 36229949
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical outcomes at 2 years of the Absorb bioresorbable vascular scaffold versus the Xience drug-eluting metallic stent in patients presenting with acute coronary syndrome versus stable coronary disease-AIDA trial substudy.
    Tijssen RYG; van der Schaaf RJ; Kraak RP; Vink MA; Hofma SH; Arkenbout EK; Weevers APJD; Kerkmeijer LSM; Onuma Y; Serruys PW; Beijk MAM; Koch KT; Baan J; Vis MM; Piek JJ; Tijssen JGP; Henriques JPS; de Winter RJ; Wykrzykowska JJ
    Catheter Cardiovasc Interv; 2020 Jan; 95(1):89-96. PubMed ID: 30968559
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prospective, randomized trial of bioresorbable scaffolds vs. everolimus-eluting stents in patients undergoing coronary stenting for myocardial infarction: the Intracoronary Scaffold Assessment a Randomized evaluation of Absorb in Myocardial Infarction (ISAR-Absorb MI) trial.
    Byrne RA; Alfonso F; Schneider S; Maeng M; Wiebe J; Kretov E; Bradaric C; Rai H; Cuesta J; Rivero F; Hoppmann P; Schlichtenmaier J; Christiansen EH; Cassese S; Joner M; Schunkert H; Laugwitz KL; Kastrati A
    Eur Heart J; 2019 Jan; 40(2):167-176. PubMed ID: 30520980
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term outcomes of bioresorbable vascular scaffold in ST-elevation myocardial infarction.
    de Hemptinne Q; Picard F; Ly HQ; Ibrahim R; Asgar AW; de Guise P; Doucet S; Dorval JF; Marquis-Gravel G; Levi M; L-L'allier P; Tanguay JF
    Acta Cardiol; 2018 Jun; 73(3):276-281. PubMed ID: 28954592
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Onuma Y; Serruys PW; Muramatsu T; Nakatani S; van Geuns RJ; de Bruyne B; Dudek D; Christiansen E; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Garcia-Garcia HM; Veldhof S; Rapoza R; Ormiston JA
    JACC Cardiovasc Interv; 2014 Dec; 7(12):1400-11. PubMed ID: 25523532
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The 1‑year safety and efficacy outcomes of Absorb bioresorbable vascular scaffolds for coronary artery disease treatment in diabetes mellitus patients: the ABSORB DM Benelux study.
    Hommels TM; Hermanides RS; Rasoul S; Berta B; IJsselmuiden AJJ; Jessurun GAJ; Benit E; Pereira B; De Luca G; Kedhi E
    Neth Heart J; 2019 Nov; 27(11):541-549. PubMed ID: 31197750
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mid-term safe and effective profile of the Magmaris scaffold in percutaneous coronary intervention: a prospective, single-center study.
    Truong BQ; Tran H; Nguyen VX; Nguyen CD; Nguyen KD; Vu VH
    Front Cardiovasc Med; 2023; 10():1194933. PubMed ID: 37304961
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Second-generation magnesium scaffold Magmaris: device design and preclinical evaluation in a porcine coronary artery model.
    Waksman R; Zumstein P; Pritsch M; Wittchow E; Haude M; Lapointe-Corriveau C; Leclerc G; Joner M
    EuroIntervention; 2017 Jul; 13(4):440-449. PubMed ID: 28262623
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A hybrid strategy with bioresorbable vascular scaffolds and drug eluting stents for treating complex coronary lesions.
    Jabbour RJ; Ielasi A; Tanaka A; Leoncini M; Cortese B; Grigis G; Mitomo S; Regazzoli D; Di Palma G; Rapetto C; Tespili M; Colombo A; Latib A
    Cardiovasc Revasc Med; 2017; 18(5S1):S4-S9. PubMed ID: 28314675
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan.
    Kimura T; Kozuma K; Tanabe K; Nakamura S; Yamane M; Muramatsu T; Saito S; Yajima J; Hagiwara N; Mitsudo K; Popma JJ; Serruys PW; Onuma Y; Ying S; Cao S; Staehr P; Cheong WF; Kusano H; Stone GW;
    Eur Heart J; 2015 Dec; 36(47):3332-42. PubMed ID: 26330419
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Temporal Trends in Adverse Events After Everolimus-Eluting Bioresorbable Vascular Scaffold Versus Everolimus-Eluting Metallic Stent Implantation: A Meta-Analysis of Randomized Controlled Trials.
    Montone RA; Niccoli G; De Marco F; Minelli S; D'Ascenzo F; Testa L; Bedogni F; Crea F
    Circulation; 2017 May; 135(22):2145-2154. PubMed ID: 28559495
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of bioresorbable vascular scaffolds in acute coronary syndrome: A two-center, one-year follow-up analysis.
    Iwańczyk S; Hiczkiewicz J; Araszkiewicz A; Łanocha M; Adamczak D; Faron W; Grajek S; Lesiak M
    Cardiol J; 2018; 25(4):479-486. PubMed ID: 29168541
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.